Back to top
more

Gilead Sciences (GILD)

(Real Time Quote from BATS)

$88.90 USD

88.90
926,404

-0.10 (-0.11%)

Updated Oct 28, 2024 12:12 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Gilead Sciences (GILD) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Gilead Sciences (GILD) closed the most recent trading day at $76.29, moving +0.9% from the previous trading session.

    Gilead Sciences (GILD) Gains As Market Dips: What You Should Know

    by Zacks Equity Research

    Gilead Sciences (GILD) closed the most recent trading day at $76.29, moving +0.9% from the previous trading session.

      Affimed (AFMD) Surges on Collaboration Contract with Roche (revised)

      by Zacks Equity Research

      Affimed (AFMD) inks a strategic collaboration deal with Roche to develop a host of immunotherapies for treating different types of cancer.

        Bausch (BHC) Resubmits NDA for Duobrii for Plaque Psoriasis

        by Zacks Equity Research

        Bausch Health Companies Inc. (BHC) resubmits its NDA for plaque psoriasis drug, Duobrii to the FDA and the agency has set a PDUFA action date of Feb 15, 2019.

          Ultragenyx to File NDA for LC-FAOD Candidate on Existing Data

          by Zacks Equity Research

          Ultragenyx (RARE) plans to submit an NDA for UX007 for the treatment of LC-FAOD on existing data, as per agreement with the FDA.

            Amgen's Leukemia Drug Blincyto Gets EU Nod for Pediatric Use

            by Zacks Equity Research

            Amgen's (AMGN) leukemia drug, Blincyto gets approval in EU for use in pediatric patients aged one year or older.

              Affimed (AFMD) Surges On Collaboration Contract With Roche

              by Zacks Equity Research

              Affimed (AFMD) inks a strategic collaboration deal with Roche to develop a host of immunotherapies for treating different types of cancer.

                Biotech Stock Roundup: GILD Gets EC Nod for Yescarta, AMGN Submits Kyprolis sNDA

                by Zacks Equity Research

                Regulatory and pipeline updates comprise some of the key developments in the biotech sector this week. These include Gilead's Yescarta approval in Europe.

                  Ultragenyx's Rare Disease Drug Mepsevii Gets EU Approval

                  by Zacks Equity Research

                  Ultragenyx's (RARE) Mepsevii gets European approval for the treatment of Mucopolysaccharidosis VII.

                    Bayer's Blood Thinner Xarelto Fails in Line Extension Studies

                    by Zacks Equity Research

                    Bayer (BAYRY) and partner Johnson & Johnson's drug, Xarelto shows no significant difference when compared with placebo in two late-stage phase III studies.

                      Amgen Files for Once-Weekly Regimen for Myeloma Drug Kyprolis

                      by Zacks Equity Research

                      Amgen (AMGN) submits a supplemental new drug application to the FDA, seeking an approval for once-weekly dosage of its multiple myeloma drug, Kyprolis, combined with dexamethasone (Kd).

                        Gilead's CAR-T Therapy Yescarta Gets Approval in Europe

                        by Zacks Equity Research

                        Gilead's (GILD) CAR-T therapy, Yescarta gets approval in Europe for adult patients suffering from relapsed or refractory DLBCL and PMBCL, after two or more lines of systemic therapy.

                          Zacks.com headshot

                          Bausch (BHC) Gets FDA Approval for Altreno for Acne Vulgaris

                          by Zacks.com

                          Bausch (BHC) advances its dermatology portfolio with the FDA approval of Altreno for acne vulgaris.

                            Novartis' CAR-T Therapy Kymriah Gets Approval in Europe

                            by Zacks Equity Research

                            Novartis (NVS) gets EC approval for CAR-T therapy, Kymriah, for the treatment of pediatric and young adult patients up to 25 years of age with B-cell acute lymphoblastic leukemia.

                              Novo Nordisk's Ozempic Lowers Risk of Cardiovascular Events

                              by Zacks Equity Research

                              Novo Nordisk (NVO) announces post hoc results from SUSTAIN 6 study demonstrating that Ozempic consistently reduces the risk of major cardiovascular (CV) events across type II diabetes population.

                                Why Is Gilead (GILD) Down 6.2% Since Last Earnings Report?

                                by Zacks Equity Research

                                Gilead (GILD) reported earnings 30 days ago. What's next for the company? We take a look at earnings estimates for some clues.

                                  Shire's Takhzyro Gets FDA Nod for Hereditary Angioedema

                                  by Zacks Equity Research

                                  Shire???s (SHPG) Takhzyro gets approval from the FDA for the treatment of hereditary angioedema in patients 12 years of age and older. It is the first-of-its-kind mAb preventive treatment for the same.

                                    Roche (RHHBY) Gets FDA Approval for Cobas EFGR Mutation Test

                                    by Zacks Equity Research

                                    Roche's (RHHBY) cobas EGFR Mutation Test v2 gets FDA nod as a companion diagnostic test with IRESSA.

                                      AbbVie Posts Positive Data on Elagolix for Uterine Fibroids

                                      by Zacks Equity Research

                                      AbbVie (ABBV) reports positive top-line results from a phase III extension trial on its investigational candidate Elagolix for treating uterine fibroids in women.

                                        Exact Sciences Inks Cologuard Co-Promotion Deal With Pfizer

                                        by Zacks Equity Research

                                        Exact Sciences (EXAS) reaches a co-promotion agreement with Pfizer to commercialize its non-invasive screening test for colorectal cancer, Cologuard. The stock rallies following this news.

                                          Ekta Bagri headshot

                                          4 Biotech Stocks Investors Can Bet on Post Solid Q2 Earnings

                                          by Ekta Bagri

                                          The biotech sector is expected to do well in the second half of 2018. Here we list four top biotech companies, which investors can add to their portfolio.

                                            Mallinckrodt's Stannsoporfin Gets Complete Response Letter

                                            by Zacks Equity Research

                                            Mallinckrodt's (MNK) pipeline candidate, Stannsoporfin gets a Complete Response Letter from the FDA.

                                              John Blank headshot

                                              Don't Worry About An Inverted Yield Curve...YET

                                              by John Blank

                                              The U.S. economy should remain out of recession until 2020.

                                                Alnylam Completes Enrollment in Phase III Givosiran Study

                                                by Zacks Equity Research

                                                Alnylam Pharmaceuticals (ALNY) completes enrollment in the phase III ENVISION study ahead of schedule of its pipeline candidate, givosiran.

                                                  Pacira (PCRX) Rides High on Robust Exparel Performance

                                                  by Zacks Equity Research

                                                  Pacira (PCRX) focuses on improving sales of its flagship product Exparel. The drug's label expansion programs also look encouraging.